Moleculin Biotech is trading at $8.92, up 5.44% in after-hours trading on November 4, 2026, after interim Phase 2/3 results showed complete remission rates of 43% and 36% in the Annamycin arms, versus 12% in the placebo arm. - The Data Monitoring Committee recommended continuing the study without amendment; the data will be presented at the December ASH meeting. - Broad U.S. indices also rose; no trading-volume details were available.